Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05937074 · ClinicalTrials.gov registry record
Metabolic Response to Food in Lung Cancer
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Pennington Biomedical Research Center.
- Active
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT05937074 is a study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Pennington Biomedical Research Center. The registered enrollment target is 5 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05937074, a study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Pennington Biomedical Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.
Conditions Studied
Interventions
- OTHER Weight loss (%)
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05937074
The ClinicalTrials.gov registry entry for NCT05937074 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (98% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Weight loss (%) is the first listed.
NCT05937074 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT05937074 about?
NCT05937074 is a clinical study titled "Metabolic Response to Food in Lung Cancer". This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.
What is the current status of trial NCT05937074?
This trial is currently active not recruiting. The enrollment target is 5 participants. The study started on 2023-07-18. Estimated completion is 2026-06-30.
What conditions does trial NCT05937074 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT05937074?
The interventions under investigation include: Weight loss (%) (OTHER).
Who is sponsoring clinical trial NCT05937074?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05937074 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.